Commercial Services and Supplies
Company Overview of Juvenile Diabetes Research Foundation International Inc.
Juvenile Diabetes Research Foundation International Inc. (JDRF) is a not-for-profit organization that focuses on juvenile diabetes cure research and development services. The organization offers grants for diabetes clinical trials to laboratories, educational institutions, and pharmaceutical and medical research companies. JDRF was founded in 1970 and is headquartered in New York City with an additional office in Houston, Texas.
120 Wall Street
New York, NY 10005-4001
Founded in 1970
Key Executives for Juvenile Diabetes Research Foundation International Inc.
Executive Vice President for Development and Chief Operating Officer
Vice President-Customer Services
President of Long Island Chapter
Compensation as of Fiscal Year 2013.
Juvenile Diabetes Research Foundation International Inc. Key Developments
JDRF Announces New Guide for Parents of Teenagers with Type 1 Diabetes
Oct 31 13
JDRF has released a new, comprehensive resource for parents of teenagers with type 1 diabetes (T1D), designed to help address the myriad of questions and issues most common to adolescents ages 12-18 with the disease, whether newly-diagnosed or long-established. The JDRF Teen Toolkit includes valuable tips and information about daily issues -- such as mood swings, academic performance, and friendships -- as well as more specific challenges -- such as driving with T1D and the effects of hormonal changes on blood-glucose control.
Juvenile Diabetes Research Foundation International Inc. Announces Partnerships with Xeris Pharmaceuticals, Inc. and Latitude Pharmaceuticals Inc. to Support the Development Soluble Glucagon Formulation
Jun 20 13
Juvenile Diabetes Research Foundation International Inc. announced partnerships with both Xeris Pharmaceuticals, Inc. and Latitude Pharmaceuticals Inc., to support the development soluble glucagon formulations--an important step toward the advancement of future generation, fully automated and multi-hormonal artificial pancreas systems for people with type 1 diabetes (T1D). First-generation artificial pancreas systems currently being tested in JDRF-supported outpatient clinical trials use technologies already available; they combine a continuous glucose monitor (CGM) with an insulin pump using computer software, to partially automate the right amount of insulin delivery at the right times for people with T1D. While first-generation artificial pancreas systems will deliver insulin, one of the aspects of future generations will be their ability to deliver multiple hormones, such as glucagon. Glucagon is a naturally occurring hormone that raises blood-sugar levels to prevent hypoglycemia (low blood sugar), but its regulation is impaired in people with T1D, for whom hypoglycemia can be dangerous. In a healthy pancreas, it complements the function of insulin to provide the natural fine-tuning of blood-glucose control, and previous studies supported by JDRF and others have shown that the addition of glucagon to insulin treatment in T1D reduces the frequency of hypoglycemia.
JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes
Jun 18 13
JDRF and BD (Becton, Dickinson and Company) are accelerating the development of new products that combine BD's proprietary insulin infusion and glucose sensing technologies through a new collaboration. This new, three-year commitment is an extension of existing JDRF-BD collaborations focused on type 1 diabetes (T1D). Many patients with T1D not only take daily insulin via an insulin pump -- requiring a catheter to be placed in the body for a number of days -- but are also checking their glucose levels via a continuous glucose monitor (CGM), which also requires a catheter-like sensor to be placed in the body for a number of days. While BD has been working to improve the products used for insulin infusion and CGM, the new collaboration with JDRF will enable additional research to develop a single optimized device that will perform both functions and eliminate the need and complexities of multiple in-dwelling catheters. The ability to perform these discrete metabolic actions automatically and accurately, with little patient intervention, defines the artificial pancreas concept.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|